You are here

Biolidics launches IPO to raise S$6.1m

BT_20181212_LMXIPO12_3641074.jpg
Ivan Lew, executive director and CEO of Biolidics, with the company's patented technology that can separate cancer cells from blood to test for the presence of cancer.

Singapore

MEDICAL technology company Biolidics on Tuesday launched an initial public offering (IPO) of 27.5 million new shares at S$0.28 each. The placement is in conjunction with its proposed listing on the Catalist board on Dec 19.

The shares will be placed out to retail and...

sentifi.com

Market voices on: